Stephen Davis is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 27 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1700 Springhill Ave
Suite 100
Mobile, AL 366041407
Telephone
251-435-1200Registry record last updated 8 Jul 2007.
Clinical trials
27 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202517 payments
- Amgen Inc.Program year202512 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
30.6%Statin9%Atorvastatin Calcium44%Pravastatin Sodium27%Rosuvastatin Calcium15%Simvastatin13%Lovastatin1%Part D<11 patientsAngiotensin receptor blocker (ARB)5.1%Losartan Potassium78%Losartan-Hydrochlorothiazide18%Irbesartan4%Part D<11 patients+ 14 more classes in this area
Metabolism & gastrointestinal
20.6%GLP-1 receptor agonist4.8%Ozempic62%Mounjaro19%Rybelsus13%Trulicity3%Victoza 2-Pak3%Part D<11 patientsProton pump inhibitor4.2%Omeprazole69%Pantoprazole Sodium20%Esomeprazole Magnesium11%Part D≥79 patients+ 11 more classes in this area
Musculoskeletal
19.6%RANK Ligand Inhibitor17%Denosumab100%Part B, office-administered≥17 patientsXanthine oxidase inhibitor1.5%Allopurinol100%Part D≥37 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”